Phase I Study of 5-Fluorouracil in Children and Young Adults With Recurrent Ependymoma

PHASE1CompletedINTERVENTIONAL
Enrollment

26

Participants

Timeline

Start Date

December 31, 2011

Primary Completion Date

May 31, 2014

Study Completion Date

May 31, 2014

Conditions
Central Nervous System MalignanciesEpendymoma
Interventions
DRUG

5-fluorouracil

5-fluorouracil, bolus dose of 500 mg/m\^2 given weekly for 4 weeks followed by a two week rest period equals one cycle (6 weeks). Therapy may continue for up to 16 cycles (about 2 years).

Trial Locations (1)

38105

St. Jude Children's Research Hospital, Memphis

All Listed Sponsors
lead

St. Jude Children's Research Hospital

OTHER

NCT01498783 - Phase I Study of 5-Fluorouracil in Children and Young Adults With Recurrent Ependymoma | Biotech Hunter | Biotech Hunter